{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T11:53:05Z","timestamp":1697543585476},"reference-count":26,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.eimc.2014.06.012","type":"journal-article","created":{"date-parts":[[2015,1,7]],"date-time":"2015-01-07T21:34:17Z","timestamp":1420666457000},"page":"397-403","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Barreras para el inicio del tratamiento antirretroviral en pacientes con virus de la inmunodeficiencia humana e indicaci\u00f3n de tratamiento en Espa\u00f1a. \u00bfPor qu\u00e9 no inician tratamiento quienes lo tienen indicado? Estudio Bridgap"],"prefix":"10.1016","volume":"33","author":[{"given":"Pompeyo","family":"Viciana-Fern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicen\u00e7","family":"Falc\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Casta\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"de los Santos-Gil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juli\u00e1n","family":"Olalla-Sierra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asunci\u00f3n","family":"Hernando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabet","family":"Deig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bonaventura","family":"Clotet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hernando","family":"Knobel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Podzamczer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pere Domingo","family":"Pedrol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eimc.2014.06.012_bib0005","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1097\/QAD.0b013e328355d67b","article-title":"The HIV care continuum: No partial credit given","volume":"26","author":"McNairy","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2014.06.012_bib0010","first-page":"1618","article-title":"Center for Disease Control and Prevention. Vital signs: HIV prevention through care and treatment--United States","volume":"60","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.eimc.2014.06.012_bib0015","series-title":"Tenth International Congress on Drug Therapy in HIV infection","article-title":"Epidemiological description of the demographic and HIV disease characteristics of HIV patients who are in care but not on treatment in Spain. The PICNIT Study","author":"Domingo","year":"2010"},{"key":"10.1016\/j.eimc.2014.06.012_bib0020","series-title":"Jan 2004-May 2008. 2008 European Scientific Conference on Applied Infectious Disease Epidemiology","article-title":"Compliance with national guidelines for antiretroviral therapy initiation and initial regimen prescription in a multicentre cohort of HIV-infected patients in Spain","author":"El Omeiri","year":"2008"},{"key":"10.1016\/j.eimc.2014.06.012_bib0025","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/j.1468-1293.2009.00731.x","article-title":"The relationship between antiretroviral prescription patterns and treatment guidelines in treatment-naive HIV-1-infected patients","volume":"10","author":"Suarez-Lozano","year":"2009","journal-title":"HIV Med"},{"key":"10.1016\/j.eimc.2014.06.012_bib0030","first-page":"209","article-title":"Documento de consenso de GESIDA\/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualizaci\u00f3n Ene 2011)","volume":"29","year":"2011","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2014.06.012_bib0035","year":"2013","journal-title":"Recomendaciones de Gesida\/Plan nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana"},{"key":"10.1016\/j.eimc.2014.06.012_bib0040","year":"2013","journal-title":"Recomendaciones de Gesida\/Plan nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana."},{"key":"10.1016\/j.eimc.2014.06.012_bib0045","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.eimc.2008.11.002","article-title":"Panel de expertos de Gesida y Plan Nacional sobre el Sida. Recomendaciones de Gesida\/Plan nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana. (Actualizaci\u00f3n Feb de 2009)","volume":"27","year":"2009","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2014.06.012_bib0050","first-page":"602","article-title":"Panel de expertos de Gesida y Plan Nacional sobre el Sida. Documento de consenso de Gesida\/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana. (Actualizaci\u00f3n enero 2013)","volume":"31","year":"2013","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2014.06.012_bib0055","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(09)60612-7","article-title":"Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: A collaborative analysis of 18 HIV cohort studies","volume":"373","author":"Sterne","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2014.06.012_bib0060","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1056\/NEJMoa0807252","article-title":"Effect of early versus deferred antiretroviral therapy for HIV on survival","volume":"360","author":"Kitahata","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2014.06.012_bib0065","doi-asserted-by":"crossref","first-page":"509","DOI":"10.7326\/0003-4819-154-8-201104190-00001","article-title":"When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study","volume":"154","author":"Cain","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eimc.2014.06.012_bib0070","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1001\/archinternmed.2011.401","article-title":"Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters","volume":"171","year":"2011","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.eimc.2014.06.012_bib0075","first-page":"CD009153","article-title":"Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples","author":"Anglemyer","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eimc.2014.06.012_bib0080","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa1105243","article-title":"Prevention of HIV-1 infection with early antiretroviral therapy","volume":"365","author":"Cohen","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2014.06.012_bib0085","doi-asserted-by":"crossref","first-page":"c2205","DOI":"10.1136\/bmj.c2205","article-title":"Combined antiretroviral treatment and heterosexual transmission of HIV-1: Cross sectional and prospective cohort study","volume":"340","author":"Del Romero","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.eimc.2014.06.012_bib0090","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/sti.2010.042622","article-title":"Estimating the risk of HIV transmission from homosexual men receiving treatment to their HIV-uninfected partners","volume":"87","author":"Hallett","year":"2011","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.eimc.2014.06.012_bib0095","first-page":"315","article-title":"HIV-1 treatment as prevention: The good, the bad, and the challenges","volume":"6","author":"Smith","year":"2011","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.eimc.2014.06.012_bib0100","doi-asserted-by":"crossref","first-page":"e11068","DOI":"10.1371\/journal.pone.0011068","article-title":"Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco","volume":"5","author":"Das","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.eimc.2014.06.012_bib0105","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1097\/QAD.0b013e328355713d","article-title":"Does ART prevent HIV transmission among MSM?","volume":"26","author":"Muessig","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2014.06.012_bib0110","unstructured":"Organizaci\u00f3n Mundial de la Salud. WHO and U.S. NIH Working Group Meeting on Treatment for HIV Prevention among MSM: What additional evidence is required? Geneva, 26-27 October 2011 [consultado 5 May 2013]. Disponible en: http:\/\/www.who.int\/hiv\/pub\/msm_meeting_report.pdf"},{"key":"10.1016\/j.eimc.2014.06.012_bib0115","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/2047-783X-15-3-93","article-title":"HAART and the liver: Friend or foe?","volume":"15","author":"Pineda","year":"2010","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.eimc.2014.06.012_bib0120","series-title":"Guidelines version 6.1-November","year":"2012"},{"key":"10.1016\/j.eimc.2014.06.012_bib0125","unstructured":"Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents [actualizado 12 Feb 2013]. Disponible en: http:\/\/aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf, consultado el 05\/05\/2013"},{"key":"10.1016\/j.eimc.2014.06.012_bib0130","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0140-6736(02)09411-4","article-title":"Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies","volume":"360","author":"Egger","year":"2002","journal-title":"Lancet"}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X14002845?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X14002845?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T12:52:28Z","timestamp":1537966348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X14002845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0213005X14002845"],"URL":"https:\/\/doi.org\/10.1016\/j.eimc.2014.06.012","relation":{},"ISSN":["0213-005X"],"issn-type":[{"value":"0213-005X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Barreras para el inicio del tratamiento antirretroviral en pacientes con virus de la inmunodeficiencia humana e indicaci\u00f3n de tratamiento en Espa\u00f1a. \u00bfPor qu\u00e9 no inician tratamiento quienes lo tienen indicado? Estudio Bridgap","name":"articletitle","label":"Article Title"},{"value":"Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eimc.2014.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.","name":"copyright","label":"Copyright"}]}}